PPARA and metabolic dysfunction-associated steatotic liver disease: As such, the pan‐peroxisome proliferator‐activated receptor (PPAR) agonist lanifibranor and the thyroid hormone receptor‐β agonist resmetirom are amongst the most promising drug candidates.[5] Both molecules have been shown to exert a wide range of therapeutic effects, mostly through the control of metabolic injury in hepatocytes, hepatic stellate cell (HSC) activation, and macrophage polarization.[6, 7] Despite this medical burden, until very recently no pharmacological agent was approved for the treatment of MASLD.